In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 <sup>+</sup> T cell responses
Our results highlight the transformative potential of the CisVac/α-CD137 combination in cancer immunotherapy, paving the way for further exploration of its clinical utility and long-term efficacy.
Authors
- Guanxin Liu (ORCID: https://orcid.org/0009-0000-3421-2616)
- Z Li (ORCID: https://orcid.org/0009-0006-9887-9026)
- Yuqing Nie (ORCID: https://orcid.org/0009-0007-4964-0948)
- M Q Wang (ORCID: https://orcid.org/0009-0003-2513-4662)
- Hongxin Huang (ORCID: https://orcid.org/0000-0002-8656-4266)
- Li Qiu (ORCID: https://orcid.org/0000-0003-2685-9799)
- Shupei Wei (ORCID: https://orcid.org/0009-0003-1312-4993)
- Qing Zheng (ORCID: https://orcid.org/0000-0001-8839-104X)
- Zhou Junfeng (ORCID: https://orcid.org/0009-0005-0452-464X)
- Z. Zhang (ORCID: https://orcid.org/0000-0003-1175-9621)
- Tao Chen (ORCID: https://orcid.org/0000-0002-8433-2509)
- Jun Liu (ORCID: https://orcid.org/0000-0002-9565-5207)
- Tao Lu (ORCID: https://orcid.org/0009-0009-0926-0451)
- Danqing Huang (ORCID: https://orcid.org/0009-0001-8911-3874)
- Lanfang Chen (ORCID: https://orcid.org/0009-0002-7031-9060)
- Qibin Leng (ORCID: https://orcid.org/0000-0002-4768-1312)
- Qi Chen (ORCID: https://orcid.org/0009-0005-4968-4401)
Institutions
- Army Medical University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Zigong First People's Hospital (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Nanjing University (CN)
- University of Hong Kong (HK)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-011665
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00